Oral Terbinafine Should NOT Be Used in Patients with Mildly Elevated Transaminases for Tinea Corporis
Systemic terbinafine is not recommended in patients with active or chronic liver disease, and baseline liver function tests are required before initiating treatment 1. The FDA drug label and British Association of Dermatologists guidelines explicitly state this contraindication, prioritizing patient safety over treatment of a non-life-threatening condition like tinea corporis.
Key Evidence Against Use
Contraindications from Guidelines and Drug Labels
The most authoritative sources are clear:
- Griseofulvin guidelines list "severe liver disease" as a contraindication 2, and while terbinafine's contraindications aren't explicitly stated in the tinea capitis guidelines, the onychomycosis guidelines are definitive
- The British Association of Dermatologists' onychomycosis guidelines (2014) explicitly state: "systemic terbinafine is not recommended in patients with active or chronic liver disease" 1
- Baseline liver function tests and complete blood count are recommended before starting terbinafine, particularly in patients with history of heavy alcohol consumption, hepatitis, or haematological abnormalities 1
- The FDA drug label mandates measurement of serum transaminases (ALT and AST) before taking terbinafine 3
Hepatotoxicity Risk Profile
While rare, the hepatotoxicity risk is real and potentially severe:
- Rare reports of serious hepatic toxicity have occurred, usually in patients with pre-existing liver disease 1
- Terbinafine has been associated with liver problems that can lead to the need for liver transplant or death 3
- Patients must be advised to immediately report symptoms of liver injury (persistent nausea, anorexia, fatigue, vomiting, right upper abdominal pain, jaundice, dark urine, pale stools), and treatment should be discontinued 3
Alternative Approach for Tinea Corporis
For tinea corporis specifically, you have safer options:
Topical Therapy First-Line
- Topical terbinafine 1% formulations achieve mycological cure in >80% of patients with tinea corporis when applied once or twice daily for up to 2 weeks 4
- This avoids systemic exposure entirely in a patient with hepatic concerns
If Systemic Therapy Required
If the infection is extensive and truly requires systemic treatment:
- Consider griseofulvin instead - while it lists "severe liver disease" as a contraindication 2, the threshold appears higher than for terbinafine, and it has 50+ years of safety experience
- Itraconazole may be an alternative, though it also requires hepatic monitoring
- Address the underlying cause of transaminase elevation first - if reversible, treat the tinea corporis topically while optimizing liver function, then reassess need for systemic therapy
Critical Clinical Pitfall
The major pitfall here is underestimating the significance of "mildly elevated" transaminases. The guidelines don't distinguish between mild, moderate, or severe elevation - they state pre-existing liver disease is a relative or absolute contraindication. Even mild elevations suggest hepatic dysfunction that could be exacerbated by terbinafine, with potentially catastrophic consequences for what is ultimately a superficial, non-life-threatening infection.
Practical Algorithm
- Document baseline transaminase values - determine if truly "mild" (1-2x ULN) or higher
- Investigate cause of elevation - alcohol, viral hepatitis, fatty liver, medications
- Start topical terbinafine 1% cream twice daily for 2 weeks for tinea corporis 4
- If topical therapy fails and systemic treatment is absolutely necessary:
- Optimize liver function if possible
- Consider griseofulvin as safer alternative
- If terbinafine must be used, obtain informed consent about hepatotoxicity risk
- Monitor LFTs weekly for first month, then every 2 weeks
- Discontinue immediately if transaminases worsen
The risk-benefit ratio does not favor oral terbinafine in this scenario when safer alternatives exist for a condition that poses no mortality risk.